Faster Access In England Under NICE-MHRA Scheme Hinges On ‘Optimal’ Drug Status

 
• By Eliza Slawther
  
Companies that want to benefit from faster HTA decisions in England must be ready to submit evidence early (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from Europe